Gridelli Cesare
Division of Medical Oncology, S.G. Moscati Hospital, Via Circumvallazione, 83100-Avellino, Italy.
Anticancer Res. 2003 May-Jun;23(3C):2773-82.
Nausea and vomiting are typical side-effects of cancer therapy. The management of acute-onset emesis (< 24 hours post-treatment) has improved markedly in recent years and the 5-HT3-receptor antagonists are widely regarded as the antiemetic 'gold standard' during this period. Delayed-onset emesis (> 24 hours post-treatment), however, still represents a therapeutic challenge. Available data indicates that the 5-HT3-receptor antagonists are at least as good as conventional antiemetics in controlling delayed-onset emesis, and that their efficacy in this setting may be improved by the addition of a corticosteroid. As a result, antiemetic guidelines recommend the addition of a 5-HT3-receptor antagonist for the treatment of delayed emesis, particularly for high-risk patients.
恶心和呕吐是癌症治疗的典型副作用。近年来，急性起病呕吐（治疗后<24小时）的管理有了显著改善，5-羟色胺3（5-HT3）受体拮抗剂在此期间被广泛视为止吐的“金标准”。然而，延迟性呕吐（治疗后>24小时）仍然是一个治疗挑战。现有数据表明，5-HT3受体拮抗剂在控制延迟性呕吐方面至少与传统止吐药一样有效，并且在这种情况下，添加皮质类固醇可能会提高其疗效。因此，止吐指南建议添加5-HT3受体拮抗剂来治疗延迟性呕吐，特别是对于高危患者。
